Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Auranofin PK in Healthy Subjects
NCT02089048Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of auranofin in amebiasis, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Plasma concentrations of gold at Day 126. Started Apr 2014; status: completed.
02
Drugs
auranofin
03
Conditions
amebiasis
Beyond the preview
Go deeper on NCT02089048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02089048.